Faculty of Medicine, Tehran University of Medical Sciences, Medicine, Tehran, Iran.
Faculty of Medicine, Iran University of Medical Sciences, Medicine, Tehran, Iran.
Neurosurg Rev. 2022 Oct;45(5):3157-3170. doi: 10.1007/s10143-022-01853-w. Epub 2022 Aug 27.
In recent years, intracranial aneurysms have been widely treated with endovascular methods. The anterior communicating artery (Acom) is the most common site of intracranial aneurysms. Despite its effectiveness, endovascular interventions can be associated with various intra-procedural and post-procedural complications. A systematic review of the literature was performed through PubMed, Embase, Scopus, and Web of Sciences databases up to March 18, 2022. The pooled rates of intra-procedural complications, mortality, procedure-related morbidities, the immediate and late aneurysm occlusion, and also the necessity for retreatment were calculated by applying random-effects models. A total of 41 articles with 4583 patients were included in the meta-analysis. The pooled rate of overall intra-procedural complications was 9.6% (95% CI: 7.7 to 11.8%). The initial rupture status and also type of EVT procedure did not affect the overall complication rate. The pooled rate of intra-procedural thrombosis, aneurysm rupture, coil prolapse, and early aneurysm rebleeding were 6.1% (95% CI: 4.5 to 8.2%); 4.2% (95% CI: 3.4 to 5.2%), 4.7% (95% CI: 3.2 to 6.7%), and 2.2% (95% CI: 1.5 to 3.2%), respectively. Our analysis showed that intra-procedural mortality occurred in 1.7% (95% CI: 1.1 to 2.5%) and procedure-related permanent morbidities in 3.3% (95% CI: 2.3 to 4.7%) of patients. Endovascular methods achieved complete and near to complete aneurysm occlusion (Raymond-Roy occlusion classification 1 and 2) in 89.2% (95% CI: 86.4 to 92.5%) of cases post-procedure, and 9.5% (95% CI: 7.3 to 12.4%) of patients needed retreatment due to recanalization in follow-ups. Endovascular treatment can serve as an acceptable method for Acom aneurysms. However, improved endovascular treatment equipment and new techniques provide more satisfactory outcomes for complicated cases.
近年来,颅内动脉瘤广泛采用血管内方法治疗。前交通动脉(Acom)是颅内动脉瘤最常见的部位。尽管血管内干预措施有效,但也可能与各种术中及术后并发症相关。通过 PubMed、Embase、Scopus 和 Web of Sciences 数据库对截至 2022 年 3 月 18 日的文献进行系统评价。通过随机效应模型计算术中并发症、死亡率、与操作相关的发病率、即刻和晚期动脉瘤闭塞率以及再次治疗的必要性的汇总率。共纳入 41 项研究,共 4583 例患者。总体术中并发症的汇总率为 9.6%(95%CI:7.7%至 11.8%)。初始破裂状态和血管内治疗类型均不影响总并发症发生率。术中血栓形成、动脉瘤破裂、线圈突出和早期动脉瘤再出血的汇总率分别为 6.1%(95%CI:4.5%至 8.2%)、4.2%(95%CI:3.4%至 5.2%)、4.7%(95%CI:3.2%至 6.7%)和 2.2%(95%CI:1.5%至 3.2%)。我们的分析表明,术中死亡率为 1.7%(95%CI:1.1%至 2.5%),与操作相关的永久性发病率为 3.3%(95%CI:2.3%至 4.7%)。血管内方法在术后达到完全和接近完全的动脉瘤闭塞(Raymond-Roy 闭塞分类 1 和 2)的比例为 89.2%(95%CI:86.4%至 92.5%),9.5%(95%CI:7.3%至 12.4%)的患者在随访中因再通需要再次治疗。血管内治疗可以作为 Acom 动脉瘤的一种可接受的方法。然而,改进的血管内治疗设备和新技术为复杂病例提供了更满意的结果。